Toggle navigation
Home
Search
Services
Blog
Contact
About
Development of an Antidote for E coli 0157 - H7 Verotoxin
Kink, John
Ophidian Pharmaceuticals, Inc., Madison, WI, United States
Search 3 grants from John Kink
Search grants from Ophidian Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
In Vivo Model of Epstein-Barr Virus Latency
Gene/Environment Interactions in Parkinson's Disease
Improving Quality of Life Outcomes in Asthma Patients
In Vivo Assessment of Tumor Receptor Levels Using Pet
Egf Receptor Regulation in Human Tumor Specimens
Recently added grants:
Structural mechanisms of sliding clamp loader ATPases
Epigenetic gene regulation in Arabidopsis
Development of Allosteric Modulators of Phosphatidylinositol 3-Kinase
Biochemistry, biology and diversity of Fic domains
Y Chromosome Evolution
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44DK048210-02
Application #
2148352
Study Section
Special Emphasis Panel (ZRG5-MBC-2 (01))
Project Start
1994-06-01
Project End
1998-03-31
Budget Start
1996-04-01
Budget End
1997-03-31
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Ophidian Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Madison
State
WI
Country
United States
Zip Code
53711
Related projects
NIH 1997
R44 DK
Development of an Antidote for E coli 0157 - H7 Verotoxin
Kink, John / Ophidian Pharmaceuticals, Inc.
NIH 1996
R44 DK
Development of an Antidote for E coli 0157 - H7 Verotoxin
Kink, John / Ophidian Pharmaceuticals, Inc.
Comments
Be the first to comment on this grant